Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Institutional Investment Fuels Provident Financial Services Shares

Dieter Jaworski by Dieter Jaworski
September 18, 2025
in Analysis, Banking & Insurance, Insider Trading
0
Provident Services Stock
0
SHARES
125
VIEWS
Share on FacebookShare on Twitter

Provident Financial Services (NYSE: PFS) experienced modest share price appreciation on Wednesday, September 17, 2025, closing 0.2% higher. This upward movement coincided with a notable institutional investment that signals growing confidence in the financial institution’s prospects.

Major Stake Increase by Investment Firm

In a significant display of conviction, investment management company Empowered Funds LLC substantially increased its position in Provident Financial Services by 22.1%. This acquisition brings the firm’s total holdings to 323,515 shares with an approximate market value of $5.6 million. Such substantial institutional accumulation typically indicates strong belief in a company’s operational trajectory and future performance.

Trading Activity and Market Performance

While the stock gained ground, trading volume reached only 323,199 shares—significantly below the 90-day average volume of 641,042 shares. This lighter-than-usual activity suggests the price advance occurred with limited market participation.

Key Performance Indicators:
* Recent Performance: +0.2% on September 17, 2025
* Institutional Activity: Empowered Funds increases stake by 22.1%
* Q2 2025 Earnings: $0.55 EPS (consensus estimate: $0.50)
* Q2 2025 Revenue: $214.17 million (consensus estimate: $213.39 million)
* Dividend: $0.24 per share (4.8% yield)
* Price Target: $22.70 with “Buy” rating

Strong Fundamental Backdrop

The company’s second quarter 2025 financial results demonstrated robust operational performance, exceeding analyst expectations on both top and bottom lines. Earnings per share reached $0.55, surpassing the $0.50 consensus estimate, while revenue of $214.17 million exceeded projections of $213.39 million.

Should investors sell immediately? Or is it worth buying Provident Services?

Credit quality metrics showed improvement with non-performing assets declining to 0.44% of total assets. Pre-tax, pre-provision income reached $99.6 million, representing 1.64% of average assets. The company also achieved a record net interest income of $187 million.

Analyst Consensus Remains Positive

Market analysts maintain a favorable outlook on Provident Financial Services, with the majority recommending the stock as a “Buy.” The average price target of $22.70 suggests confidence in the company’s valuation potential.

The institution’s strategic initiatives, including its recent merger with Lakeland Bancorp, are expected to drive additional growth and enhance operational efficiency. These developments should support continued strong financial performance through the end of 2025.

Technical and Valuation Metrics

With a market capitalization of $2.56 billion, the company trades at a P/E ratio of 11.09. The stock’s beta of 0.94 indicates lower volatility compared to the broader market. Current share prices remain well above both the 50-day moving average of $19.00 and the 200-day moving average of $17.56, confirming the maintenance of an upward trend.

Ad

Provident Services Stock: Buy or Sell?! New Provident Services Analysis from February 8 delivers the answer:

The latest Provident Services figures speak for themselves: Urgent action needed for Provident Services investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 8.

Provident Services: Buy or sell? Read more here...

Tags: Provident Services
Dieter Jaworski

Dieter Jaworski

About Dieter Jaworski From a numbers-obsessed child to creating his first investment newsletter. Even as a child, Dieter Jaworski's mother couldn't believe how fascinated he was with numbers. This early passion for mathematics and data analysis laid the foundation for a successful career in financial markets and investment analysis.
Areas of Expertise:
  • Quantitative Analysis
  • Financial Newsletter Publishing
  • Data-Driven Investment Strategies
  • Market Pattern Recognition
Dieter's unique approach combines his natural affinity for numbers with decades of market experience, providing investors with data-driven insights and practical investment strategies.

Related Posts

Quanterix Stock
Analysis

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026
Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Repay Holdings Stock
Analysis

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Next Post
Deciphera Stock

European Approval for ROMVIMZA™ Provides Major Boost to Deciphera

Wisdomtree Investments Stock

WisdomTree's Digital Push Fuels Record Performance Amid Strategic Expansion

Bancorp Inc (The) Stock

Bancorp Inc: Assessing the Fintech Surge and Valuation Divide

Recommended

Biotechnology Stock Exchange

Analysts Bullish on Dynatrace with Price Targets on the Rise

2 years ago
The Trade Desk Stock

The Trade Desk Faces Mounting Pressure as Amazon Strikes Netflix Deal

5 months ago

Analyst Reaffirms Buy Rating on International Seaways with 66 Price Target

2 years ago
Biotechnology Stock Bull Market

KeyBanc Analyst Raises Price Target and Maintains Overweight Rating on Repligen NASDAQ RGEN

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

Repay Holdings: Annual Report to Test Strategic Refinancing Success

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Trending

Puma Biotechnology Stock
Earnings

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

by Jackson Burston
February 8, 2026
0

Investor attention is now firmly fixed on February 26, 2026, as Puma Biotechnology prepares to release its...

Quanterix Stock

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026
Design Therapeutics Stock

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Puma Biotechnology Sets Date for Full-Year Financial Disclosure
  • Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test
  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com